Ropivacaine Hydrochloride (Naropin) Injection Shortage: Supply Updates and Manufacturer Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Ropivacaine Hydrochloride, a common anesthetic injection, is facing supply challenges with multiple manufacturers reporting limited availability or backorders.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Ropivacaine.
What's in Shortage
Ropivacaine Hydrochloride Injection, also known by the brand name Naropin, is currently listed on the FDA drug shortage database. This medication is categorized as an anesthesia product. The shortage affects various concentrations and presentations of the injection, including 2 mg/mL, 5 mg/mL, 7.5 mg/mL, and 10 mg/mL.
Which Manufacturers Are Affected
Several manufacturers are currently reporting varying levels of availability for Ropivacaine Hydrochloride:
- Caplin Steriles, Ltd. (Marketed by Baxter): Reports limited availability for certain 2 mg/1 mL and 5 mg/1 mL presentations. Other 5 mg/1 mL and 10 mg/1 mL presentations are currently available. (Contact: 888-229-0001)
- Eugia US LLC: Reports that specific 7.5 mg/1 mL and 10 mg/1 mL presentations are on backorder with a recovery date to be determined. Several other concentrations remain available. (Contact: 888-238-7880)
- Fresenius Kabi USA, LLC: Multiple presentations of Naropin (2 mg/1 mL, 5 mg/1 mL, 7.5 mg/1 mL, and 10 mg/1 mL) are currently unavailable, with some having no release date available at this time. However, several other specific NDC presentations remain available. (Contact: 888-386-1300)
Why There's a Shortage
The official reason provided for this shortage is listed as "Other." No further specific details regarding manufacturing or supply chain issues were disclosed in the source data.
What Patients Should Do
If you are scheduled for a procedure requiring anesthesia, please be aware of the following steps:
- Consult Your Healthcare Provider: Discuss any concerns regarding your treatment plan with your doctor or surgeon. They are best equipped to manage your care during a shortage.
- Speak with the Pharmacy: Hospital or clinic pharmacists can provide the most current information on local inventory and supply status.
- Contact Manufacturers: For specific supply inquiries or to check on the status of a particular presentation, you may use the contact numbers provided above.
Disclaimer: Patients should always consult their healthcare provider regarding medication changes or treatment alternatives.
Source
Information provided by the FDA Drug Shortage Database.
- Initial Posting Date: 12/22/2020
- Last Updated: 02/02/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.